Quest Diagnostics stock heads toward October 22 results

Published on 09/29/2026 at 14:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Quest Diagnostics stock was EUR 209.60 at Lang & Schwarz on September 29, 2026. Q2 revenue rose 10.2 percent to USD 3.04 billion and adjusted EPS reached USD 3.12.

Automatisierter Laboranalysator mit Blutproben-Röhrchen in klinischem Diagnostiklabor — Quest Diagnostics US74834L1008 zeigt automatisierten Laboranalysator mit Blutproben in modernem Diagnostiklabor fotorealistisch dargestellt, Illustration mit AI erstellt.

Quest Diagnostics stock (ISIN US74834L1008) was trading at EUR 209.60 at Lang & Schwarz on September 29, 2026, down 0.31 percent versus the prior close of EUR 210.25. The next scheduled company checkpoint is October 22, 2026, when Quest Diagnostics will publish third-quarter results before the US market opens.

October 22 sets the next checkpoint

Trivano reported on September 22, 2026, that Quest Diagnostics will release its third-quarter 2026 results on October 22, 2026, before the market opens. The conference call is scheduled for 8:30 a.m. ET, giving investors a defined date for the next update on demand, margins and full-year guidance.

The date follows a strong second quarter. Yahoo Finance reported that Q2 2026 revenue reached USD 3.04 billion, up 10.2 percent from the prior year, while adjusted diluted EPS increased 19.1 percent to USD 3.12 from USD 2.62.

Volume supports the revenue case

The earnings-call figures point to volume as the central operating driver. Requisitions increased 13.1 percent year over year in Q2 2026, while diagnostic information services revenue grew 10.3 percent, according to Yahoo Finance.

Quest also raised its full-year 2026 outlook to USD 11.95 billion to USD 12.05 billion of revenue and USD 11.05 to USD 11.25 of adjusted EPS. The range gives the October report a clear test: management will need to show that volume growth is translating into earnings despite investments and wage pressure.

Truist lifts target to USD 260

MarketBeat reported on September 21, 2026, that Truist Financial raised its Quest Diagnostics price target from USD 250.00 to USD 260.00 while retaining a Hold rating. The target revision contrasts with the stock's Lang & Schwarz price of EUR 209.60 and leaves the October results as the next operating evidence for the valuation.

Stock trades at EUR 209.60

At 2:03 p.m. CEST on September 29, 2026, Quest Diagnostics stock was trading at EUR 209.60 at Lang & Schwarz, down 0.31 percent against the EUR 210.25 prior close of September 28, 2026. Its market capitalization was USD 26.2 billion as of September 28, 2026, while the 52-week range stood at USD 171.18 to USD 248.84.